Selected article for: "acute respiratory syndrome and lupus arthritis"
Author: Jung, Sun-Young; Kim, Myo-Song; Kim, Min-Chul; Choi, Seong-Ho; Chung, Jin-Won; Choi, Sang Tae
Title: Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study
  • Cord-id: s6yvvj8l
  • Document date: 2020_12_11
    • ID: s6yvvj8l
    Snippet: OBJECTIVES: Early in vitro studies have suggested that hydroxychloroquine (HCQ) is a potentially useful drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. This study was conducted to determine whether HCQ had a preventive effect on coronavirus disease 2019 (COVID-19) in rheumatic disease patients who were taking HCQ. METHODS: We conducted a population-based retrospective cohort study using the records of the Korean Health Insurance Review and Assessment (HIRA)
    Document: OBJECTIVES: Early in vitro studies have suggested that hydroxychloroquine (HCQ) is a potentially useful drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. This study was conducted to determine whether HCQ had a preventive effect on coronavirus disease 2019 (COVID-19) in rheumatic disease patients who were taking HCQ. METHODS: We conducted a population-based retrospective cohort study using the records of the Korean Health Insurance Review and Assessment (HIRA) claim records. The clinical data of patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) who were tested for SARS-CoV-2 were investigated. We compared the attack rate of COVID-19 between those who underwent HCQ therapy within 14 days before the test for SARS-CoV-2 (HCQ users) and HCQ non-users. Data were analysed using logistic regression models, χ(2), and Student's t-tests. RESULTS: As of 15th May 2020, 2066 patients with RA or SLE were tested for COVID-19. Among them, 31.4% (649/2066) were treated with HCQ. Most HCQ users (93.7%, 608/649) were taking 200–400 mg/day recommended for the treatment of rheumatic diseases. The attack rate of COVID-19 in the HCQ users (2.3%, 15/649) did not differ from that in the HCQ non-users (2.2%, 31/1417) (p 0.86). CONCLUSIONS: HCQ prophylactic use at a usual dose did not prevent COVID-19 in patients with rheumatic disease.

    Search related documents:
    Co phrase search for related documents
    • additional analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • additional analysis and logistic regression model: 1, 2, 3, 4, 5
    • administration timing and loading dose: 1
    • administration timing and logistic model: 1, 2
    • administration timing and logistic regression: 1, 2
    • administration timing and logistic regression model: 1
    • administration timing and lupus erythematosus: 1
    • loading dose and logistic model: 1
    • loading dose and logistic regression: 1, 2
    • loading dose and logistic regression model: 1
    • logistic model and low comorbidity: 1, 2
    • logistic model and lupus erythematosus: 1, 2, 3
    • logistic regression and low comorbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • logistic regression and low comorbidity index: 1, 2
    • logistic regression and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • logistic regression model and low comorbidity: 1, 2
    • logistic regression model and lupus erythematosus: 1, 2, 3